Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
72 participants
INTERVENTIONAL
2003-02-28
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures
NCT00004817
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)
NCT01951560
Traumatic Neuroprotection and Epilepsy Prevention of Valproate Acid
NCT02027987
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)
NCT02872428
Antiepileptic Drugs and Vascular Risk Markers
NCT00774306
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
valproic acid
Valproic acid given orally 400mg twice daily
valproic acid
treatment of 1 month dosage of 400 mg BID
placebo bid
placebo
Placebo twice daily for one month
placebo bid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
valproic acid
treatment of 1 month dosage of 400 mg BID
placebo bid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wolfson Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Yair Lampl
Professor Yair Lampl
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ronit gilad, md
Role: PRINCIPAL_INVESTIGATOR
E Wolfson med center
ronit gilad, md
Role: PRINCIPAL_INVESTIGATOR
E wofson med center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.